Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2014 1
2015 1
2016 1
2018 1
2019 3
2020 4
2021 10
2022 13
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A. Bastos-Oreiro M, et al. Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr. Hemasphere. 2024. PMID: 38650598 Free PMC article. No abstract available.
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
Bastos-Oreiro M, Gutierrez A, Cabero A, López J, Villafuerte P, Jiménez-Ubieto A, de Oña R, De la Fuente A, Navarro B, Peñalver J, Martínez P, Alonso C, Infante M, Córdoba R, Perez-Montero B, Pérez de Oteyza J, González de Villambrosio S, Fernández-Caldas P, Del Campo R, García Belmonte D, Diaz-Gálvez J, Salar A, Sancho JM. Bastos-Oreiro M, et al. Cancers (Basel). 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285. Cancers (Basel). 2024. PMID: 38610963 Free PMC article.
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Gil-Alós D, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: bastos oreiro m. Front Immunol. 2024 Jan 10;14:1349296. doi: 10.3389/fimmu.2023.1349296. eCollection 2023. Front Immunol. 2024. PMID: 38268917 Free PMC article.
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.
Pagani C, Rusconi C, Dalla Pria A, Ravano E, Schommers P, Bastos-Oreiro M, Verga L, Gini G, Spina M, Arcaini L, Steffanoni S, Dalu D, Crucitti L, Lorenzi L, Balzarini P, Cattaneo C, Bongiovanni L, Rosenwald A, Facchetti F, Bower M, Ferreri AJM, Rossi G, Tucci A, Re A. Pagani C, et al. Among authors: bastos oreiro m. Blood Adv. 2024 Feb 27;8(4):968-977. doi: 10.1182/bloodadvances.2023010704. Blood Adv. 2024. PMID: 38207206 Free PMC article.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P, González-Barca E, Panizo C, Pérez JMA, Miall F, Bastos-Oreiro M, Triguero A, Banerjee L, McMillan A, Seymour E, Hirata J, de Guzman J, Sharma S, Jin HY, Musick L, Diefenbach C. Abrisqueta P, et al. Among authors: bastos oreiro m. Lancet Haematol. 2024 Feb;11(2):e136-e146. doi: 10.1016/S2352-3026(23)00345-9. Epub 2024 Jan 5. Lancet Haematol. 2024. PMID: 38190832 Clinical Trial.
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
de la Iglesia-San Sebastián I, Carbonell D, Bastos-Oreiro M, Pérez-Corral A, Bailén R, Chicano M, Muñiz P, Monsalvo S, Escudero-Fernández A, Oarbeascoa G, Fernández-Caldas P, Gómez-Centurión I, Pion M, Gayoso J, Anguita J, Kwon M, Díez-Martín JL, Buño I, Martínez-Laperche C. de la Iglesia-San Sebastián I, et al. Among authors: bastos oreiro m. Transplant Cell Ther. 2024 Mar;30(3):306.e1-306.e12. doi: 10.1016/j.jtct.2023.12.672. Epub 2024 Jan 5. Transplant Cell Ther. 2024. PMID: 38184148 Free article.
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: bastos oreiro m. Front Immunol. 2023 Aug 16;14:1243241. doi: 10.3389/fimmu.2023.1243241. eCollection 2023. Front Immunol. 2023. PMID: 37662957 Free PMC article.
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M, Avigdor A, McKinney MS, Paneesha S, Wahlin BE, Hrom JS, Cunningham D, Morley N, Canales M, Bastos-Oreiro M, Belada D, Devizzi L, Zheng F, DeMarini DJ, Jiang W, Jiang P, Lynch RC. Trněný M, et al. Among authors: bastos oreiro m. EClinicalMedicine. 2023 Aug 18;63:102130. doi: 10.1016/j.eclinm.2023.102130. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37662520 Free PMC article.
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Bastos-Oreiro M, Gutierrez A, Iacoboni G, López Corral L, Reguera JL, Abrisqueta P, Delgado J, Terol MJ, Hernani R, Martínez N, Ortíz V, Bailen R, Gomez-Centurión I, Caballero A, Sanz J, Guerra Domínguez L, Luzardo H, Mussetti A, Jiménez-Ubieto A, Sancho JM, Sureda A, Pérez A, Barba P, Kwon M, Martín García-Sancho A. Bastos-Oreiro M, et al. Transplant Cell Ther. 2023 Dec;29(12):747.e1-747.e10. doi: 10.1016/j.jtct.2023.08.026. Epub 2023 Sep 1. Transplant Cell Ther. 2023. PMID: 37659694 Free article.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM. Ribera JM, et al. Among authors: bastos oreiro m. Haematologica. 2024 Feb 1;109(2):543-552. doi: 10.3324/haematol.2023.283342. Haematologica. 2024. PMID: 37560813 Free PMC article.
52 results